Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has ...

Adagio Medical (Nasdaq:ADGM) announced today that it received FDA breakthrough device designation for its vCLAS cryoablation ...

Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced the successful ...

US FDA grants IDE approval to Innoblative’s SIRA RFA electrosurgical device for breast cancer treatment: Chicago Monday, ...

Verafeye is a four-dimensional (4D), ultrasound-based cardiac visualisation and navigation platform that generates a ...

Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the U.S.

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...

DelveInsight’s Cardiopulmonary Bypass Equipment Market Insightsreport provides the current and forecast market analysis, ...

With a focus on endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) and thoracoabdominal aortic aneurysms ( ...

Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the United States.

Every patient in the trial has met the primary safety endpoint, confirmed through PET imaging showing precise retention of the therapeutic Yttrium-90 isotope at the injection site-with no observed ...